NFA
ARGS

Nationwide Fund Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

Nationwide Fund Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-470
Closed -$4K – 3370
2017
Q1 		$4K Sell
470
-114
-20% -$7.21K ﹤0.01% 3166
2016
Q4 		$57K Buy
584
+145
+33% +$13.6K ﹤0.01% 2994
2016
Q3 		$44K Buy
439
+107
+32% +$11.2K ﹤0.01% 3063
2016
Q2 		$41K Buy
+332
New +$44.3K ﹤0.01% 3104

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Nationwide Fund Advisors's ARGS Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 470 shares — an estimated $4K sold.

Nationwide Fund Advisors first reported a position in ARGS in Q2 2016 and held it in 4 quarters. The position peaked at $57K in Q4 2016. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 470 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $4K.
  • Nationwide Fund Advisors first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Argos Therapeutics, Inc. position peaked at $57K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.